EFFICACY AND SAFETY OF BIPHASIC INSULIN ANALOGUE NOVOMIX -30 IN TYPE 2 DIABETES MELLITUS: FROM CLINICAL RESEARCH TO REAL PRACTICE


E.V.Surkova

FSBI "Endocrinological Research Center", Moscow
Biphasic insulin preparations (pre-mixed or ready-to-use insulin mixtures) include fixed proportion of short-acting insulin (ultrashort-acting) and insulin with prolonged action. Currently, this group of drugs includes preparations of both human and analogue insulins. Drug NovoMix-30 is used in the world clinical practice for over 10 years and remains one of the most studied preparation of insulin; efficacy and safety of NovoMix-30 are confirmed by numerous randomized clinical trials and large observational programs. Comparative studies of NovoMix-30 and biphasic human insulins, as well as analogues insulins with different ratios of short-acting and long-acting fractions were performed. NovoMix-30 demonstrates a high level of efficiency and safety, especially with regard to the risk of hypoglycemia and the effects on body weight. NovoMix- 30 is suitable for both initiation and for the intensification of insulin therapy, because enables the use of one drug in a single syringe insulin delivery system, with individual selection of dose and increase the number of injections, if appropriate. Furthermore, the use of a simple titration algorithm enhances adherence of patients to a regimen of therapy recommended by a physician.

About the Autors


E.V. Surkova – MD, Leading Researcher at the Department of programmed training and treatment, FSBI "Endocrinological Research Center", Moscow; e-mail: elenasurkova@mail.ru


Similar Articles


Бионика Медиа